Journal of the American Academy of Child & Adolescent Psychiatry
Early Prediction of Acute Antidepressant Treatment Response and Remission in Pediatric Major Depressive Disorder
Section snippets
Method
The data presented here are from the acute phase treatment of a single-site continuation study, Childhood Depression: Remission and Relapse (R01 MH39188; principal investigator: G.E.), the primary results of which have been published previously.16 The study was approved by the University of Texas Southwestern Medical Center at Dallas institutional review board. All participants and their parents provided written informed consent and assent before entering the study.
Participant Characteristics
More than 80% of the 168 participants completed the entire 12 weeks of acute phase of treatment. Reasons for discontinuation during the acute treatment were lack of efficacy (n = 6/168; 3.6%), moved or lost to follow-up (n = 5/168; 3.0%), withdrew consent (n = 11/168; 6.5%), noncompliance (n = 2/168; 1.2%), and adverse events (n = 8/168; 4.8%). Adverse events leading to discontinuation included rash (n = 2/168; 1.2%), multiple physical adverse events (n = 1; 0.6%), and suicide-related behaviors
Discussion
Most demographic and baseline clinical features did not predict treatment outcome in this well-characterized pediatric sample with MDD. Although some earlier studies demonstrated a few clinical characteristics that predicted outcome (e.g., depression severity, previous episodes),7, 8, 9 this study found no demographic or illness characteristics at baseline that predicted remission. Previous studies of predictors of response have not yielded consistent results, so our lack of finding here is not
References (28)
- et al.
The Texas Childhood Medication Algorithm Project: update from the Texas consensus conference panel on medication treatment for the treatment of childhood major depressive disorder
J Am Acad Child Adolesc Psychiatry
(2007) - et al.
The development of clinical practice guidelines for the diagnosis and treatment of depression
Gen Hosp Psychiatry
(1992) - et al.
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS)
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study
J Affect Disord
(1999) - et al.
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder
Psychiatry Res
(2007) Tolerability and adherence issues in antidepressant therapy
Clin Ther
(2003)- et al.
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
Psychiatry Res
(1999) - et al.
Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings
Biol Psychiatry
(2008) - et al.
Report by the ACNP Task Force on response and remission in major depressive disorder
Neuropsychopharmacology
(2006)
Review of the efficacy and safety of antidepressants in youth depression
J Child Psychol Psychiatry
Treatment for Adolescents With Depression Study (TADS) Team: fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents With Depression Study (TADS) randomized controlled Trial
JAMA
Practice parameters for the assessment and treatment of children and adolescents with depressive disorders
J Am Acad Child Adolesc Psychiatry
Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder
Arch Gen Psychiatry
Cited by (0)
The study was supported by a grant entitled Childhood Depression: Remission and Relapse (R01 MH39188) from the National Institute of Mental Health (principal investigator: G.E.). In addition, support for Dr. Tao was provided in part by the Klingenstein Third Generation Foundation Fellowship in Child and Adolescent Psychiatry. Eli Lilly provided the medication for the study but had no role in the study design or implementation, analysis of data, or authorship of this article.
Clinical trials registration information—Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00332787.